JP2020502059A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502059A5
JP2020502059A5 JP2019526282A JP2019526282A JP2020502059A5 JP 2020502059 A5 JP2020502059 A5 JP 2020502059A5 JP 2019526282 A JP2019526282 A JP 2019526282A JP 2019526282 A JP2019526282 A JP 2019526282A JP 2020502059 A5 JP2020502059 A5 JP 2020502059A5
Authority
JP
Japan
Prior art keywords
cancer
exon
mutation
pharmaceutical composition
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019526282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502059A (ja
JP7265985B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062326 external-priority patent/WO2018094225A1/en
Publication of JP2020502059A publication Critical patent/JP2020502059A/ja
Publication of JP2020502059A5 publication Critical patent/JP2020502059A5/ja
Priority to JP2023067134A priority Critical patent/JP7685550B2/ja
Application granted granted Critical
Publication of JP7265985B2 publication Critical patent/JP7265985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019526282A 2016-11-17 2017-11-17 Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 Active JP7265985B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023067134A JP7685550B2 (ja) 2016-11-17 2023-04-17 Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662423732P 2016-11-17 2016-11-17
US62/423,732 2016-11-17
US201662427692P 2016-11-29 2016-11-29
US62/427,692 2016-11-29
US201762572716P 2017-10-16 2017-10-16
US62/572,716 2017-10-16
PCT/US2017/062326 WO2018094225A1 (en) 2016-11-17 2017-11-17 Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067134A Division JP7685550B2 (ja) 2016-11-17 2023-04-17 Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物

Publications (3)

Publication Number Publication Date
JP2020502059A JP2020502059A (ja) 2020-01-23
JP2020502059A5 true JP2020502059A5 (enExample) 2021-01-07
JP7265985B2 JP7265985B2 (ja) 2023-04-27

Family

ID=62146809

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019526282A Active JP7265985B2 (ja) 2016-11-17 2017-11-17 Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP2023067134A Active JP7685550B2 (ja) 2016-11-17 2023-04-17 Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023067134A Active JP7685550B2 (ja) 2016-11-17 2023-04-17 Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物

Country Status (18)

Country Link
US (2) US11446302B2 (enExample)
EP (1) EP3541832A4 (enExample)
JP (2) JP7265985B2 (enExample)
KR (2) KR102585006B1 (enExample)
CN (2) CN117599061A (enExample)
AU (2) AU2017363199B2 (enExample)
BR (1) BR112019010020A2 (enExample)
CA (1) CA3044432A1 (enExample)
CL (1) CL2019001353A1 (enExample)
CO (1) CO2019006218A2 (enExample)
CU (1) CU20190051A7 (enExample)
EC (1) ECSP19043254A (enExample)
MA (1) MA46852A (enExample)
MX (1) MX2019005834A (enExample)
PE (1) PE20191303A1 (enExample)
PH (1) PH12019501116A1 (enExample)
TW (1) TWI782931B (enExample)
WO (1) WO2018094225A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12629375B2 (en) 2020-03-27 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111527103A (zh) * 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
CA3094108A1 (en) * 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas Systems Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
CA3101657A1 (en) * 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
SG11202012067YA (en) * 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
BR112021004527A2 (pt) * 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
CN113271948B (zh) * 2018-12-21 2024-08-16 得克萨斯大学体系董事会 治疗癌症的联合疗法
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
PH12021552110A1 (en) * 2019-03-29 2022-06-06 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
AU2020254499A1 (en) * 2019-03-29 2021-10-28 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 insertions
CN113784718A (zh) * 2019-04-17 2021-12-10 得克萨斯大学体系董事会 对携带酪氨酸激酶抑制剂抗性egfr突变的癌细胞具有抗肿瘤活性的化合物
SG11202111120VA (en) * 2019-04-17 2021-11-29 Univ Texas Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US20220296598A1 (en) * 2019-08-23 2022-09-22 Spectrum Pharmaceuticals, Inc. Poziotinib Combination with VEGFR2 Inhibitors and Methods of Use Thereof
US20230069749A1 (en) * 2020-01-29 2023-03-02 Board Of Regents, The University Of Texas System Use of poziotinib for the treatment of cancers with nrg1 fusions
CN115427456A (zh) * 2020-01-29 2022-12-02 得克萨斯州大学系统董事会 基于喹唑啉的酪氨酸激酶抑制剂在具有nrg1融合的癌症的治疗中的用途
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
CN111658650B (zh) * 2020-05-28 2022-05-06 南通大学 Mln4924在制备脉络膜新生血管治疗药物中的应用
UY39342A (es) * 2020-07-27 2022-02-25 Spectrum Pharmaceuticals Inc Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas
US12528869B2 (en) 2020-08-25 2026-01-20 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with EGFR mutations
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
JP2024505056A (ja) * 2021-01-29 2024-02-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ポジオチニブを用いてがんを処置する方法
JP2024509920A (ja) 2021-03-09 2024-03-05 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ活性化変異を欠くがんの治療
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023015149A1 (en) * 2021-08-02 2023-02-09 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
JP2026508945A (ja) 2023-03-13 2026-03-13 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ＥＧＦＲ／ｃ－Ｍｅｔ抗体と抗ＰＤ－１抗体との併用療法
CN121712773A (zh) 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗
WO2025101809A1 (en) * 2023-11-08 2025-05-15 Fate Therapeutics, Inc. Ipsc-derived t cells for solid tumor treatment
CN117587111A (zh) * 2023-11-30 2024-02-23 苏州拓维生物技术有限公司 一种快速批量筛选化合物在激酶细胞系中活性的方法
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026086737A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086740A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use and method of bispecific antibody-drug conjugates for treating tumor diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA190628A (en) 1918-12-05 1919-05-27 William J. Newton Toggle socket
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7935500B2 (en) 2002-03-26 2011-05-03 Massachusetts Institute Of Technology Identifying calcineurin activators for treatment of schizophrenia
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
KR20070108889A (ko) 2005-02-04 2007-11-13 베링거 인겔하임 인터내셔날 게엠베하 만성 비부비동염 치료용 티로신 키나제 억제제의 용도
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
BRPI0717586A2 (pt) * 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
CN101516376A (zh) * 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PL3053932T3 (pl) 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
EP2929350A4 (en) 2012-12-04 2016-11-16 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
BR112016003247B1 (pt) * 2013-08-22 2022-05-10 Taiho Pharmaceutical Co., Ltd Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12629375B2 (en) 2020-03-27 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions

Similar Documents

Publication Publication Date Title
JP2022527788A5 (enExample)
Zarkavelis et al. Current and future biomarkers in colorectal cancer
Mosrati et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
Kwon et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
CN102575295B (zh) 可用于检测braf突变的方法、引物、探针和试剂盒
EP2505673B1 (en) Polynucleotide primers for detecting PIK3CA mutations
EP2580322B1 (en) A mek 1 mutation conferring resistance to raf and mek inhibitors
WO2013172933A1 (en) Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
Huang et al. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk
WO2009068621A1 (en) Method for classifying cancer patients as responder or non-responder to immunotherapy
Clemens et al. A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients.
JP2022529016A5 (enExample)
JP2022529945A5 (enExample)
CN106148498A (zh) Kras基因突变检测试剂盒及其应用
WO2011035538A1 (zh) 用于定量检测egfr突变的试剂盒
JP2021519306A5 (enExample)
RU2020134932A (ru) Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2
JP2022527499A5 (enExample)
WO2011079524A1 (zh) 用于定量检测k-ras突变的试剂盒
Liu et al. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage
CN102796811A (zh) 检测kras突变的试剂及方法
Kim et al. PIK3CA mutations in hepatocellular carcinoma in Korea
Kostakis et al. Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population
WO2013172932A1 (en) Colon cancer tumor suppressor gene, b-defensin 1, predicts recurrence in patients with stage ii and iii colon cancer
CN114807366A (zh) 一种人肿瘤特异性braf突变检测方法